Author： Guppy Amy Jamal-Hanjani Mariam Pickering Lisa
Publisher： Future Medicine
ISSN： 1479-6694
Source： Future Oncology, Vol.7, Iss.6, 2011-06, pp. : 727-736
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Metformin is an orally available, biguanide derivative that is widely used in the treatment of Type 2 diabetes. Recent preclinical data have demonstrated that it can also act as an anticancer agent by activation of AMPK and subsequent inhibition of mTOR. Metformin is currently being investigated in several Phase II/III clinical trials. This article will review the current evidence for its mechanism of action, efficacy in preclinical and clinical models, and toxicity. Ongoing and planned studies evaluating the impact of metformin on breast cancer outcomes are also discussed.
Related content
Access to resources
Recommend
